Invesco Biotechnology & Genome ETF
PBE
70 hedge funds and large institutions have $116M invested in Invesco Biotechnology & Genome ETF in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 11 closing their positions.
5% less funds holding
Funds holding: 74 → 70 (-4)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
48% less capital inflows, than outflows
Capital inflows: $4.29M | Capital outflows: $8.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$1.49M |
| 2 |
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$1.28M |
| 3 |
Murphy Capital Management
Bedminster,
New Jersey
|
+$233K |
| 4 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$165K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.62M |
| 2 |
Virtu KCG Holdings
New York
|
-$1.58M |
| 3 |
Goldman Sachs
New York
|
-$1.18M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$823K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$617K |
PBE Hedge Fund Activity: Q3 2014 in Review
70 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2014, worth a combined $116M — up 2.1% from $113M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PBE and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 18 added.
The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.49M. The largest seller was Morgan Stanley, cutting an estimated $1.62M.
- 70 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2014, down from 74 in Q2 2014.
- Funds reported $116M of Invesco Biotechnology & Genome ETF stock for Q3 2014, up 2.1% quarter-over-quarter.
- 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2014 and 11 closed out, a net change of -4 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2014 was Baldwin Wealth Partners, an estimated $1.49M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2014 was Morgan Stanley, an estimated $1.62M sold.
Based on aggregated 13F filings for Q3 2014.